Coverage of insulin delivery devices and basal insulin analogs by US managed care organizations

Journal of Medical Economics

Volumn 14, Issue 6, 2011, Pages 720-728

  Kimball, Edward S ^a   Aagren, Mark ^a  

^a NOVO NORDISK INC   (United States)

Author keywords

Cost; Insulin analogs; Insulin vial; Insurance coverage; Neutral Protamine Hagedorn; Pen device

Indexed keywords

INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN;

ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DATA BASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HEALTH CARE ORGANIZATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MEDICARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIVATE HEALTH INSURANCE; UNITED STATES;

DEDUCTIBLES AND COINSURANCE; DRUG DELIVERY SYSTEMS; HUMANS; INSULIN, LONG-ACTING; INSURANCE COVERAGE; INSURANCE, HEALTH; MANAGED CARE PROGRAMS; MEDICARE PART D; UNITED STATES;

EID: 81255201257     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.613975     Document Type: Article

References (23)

1. Bonafede MM, Kalsekar A, Pawaskar M, et al. A retrospective database analysis of insulin use patterns in insulin-naive patients with type 2 diabetes initiating basal insulin or mixtures. Patient Prefer Adherence 2010;4:147-56
2. Perfetti R. Reusable and disposable insulin pens for the treatment of diabetes: understanding the global differences in user preference and an evaluation of inpatient insulin pen use. Diabetes Technol Ther 2010;12(1 Suppl):S79-S85
3. Lee IT, Liu HC, Liau YJ, et al. Improvement in health-related quality of life, independent of fasting glucose concentration, via insulin pen device in diabetic patients. J Eval Clin Pract 2009;15:699-703
4. Korytkowski M, Bell D, Jacobsen C, et al. A multicenter, randomized, openlabel, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25:2836-48 (Pubitemid 37510593)
5. Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy 2007;27:948-62 (Pubitemid 46986681)
6. Cooke CE, Lee HY, Tong YP, et al. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin 2010;26:231-8
7. Baser O, Bouchard J, Deluzio T, et al. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe. Adv Ther 2010;27:94-104
8. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712-25 (Pubitemid 44841979)
9. Pawaskar MD, Camacho FT, Anderson RT, et al. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: A retrospective database analysis. Clin Ther 2007;29(spec no):1294-305 (Pubitemid 351172225)
10. Lee LJ, Li Q, Reynolds MW, et al. Comparison of utilization, cost, adherence, and hypoglycemia in patients with type 2 diabetes initiating rapid-acting insulin analog with prefilled pen versus vial/syringe. J Med Econ 2011;14:75-86
11. Niskanen L. A clinical and health economic review of a prefilled insulin pen. Curr Med Res Opin 2010;26:2431-9
12. Molife C, Lee LJ, Shi L, et al. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol Ther 2009;11:529-38
13. Peyrot M, Rubin RR. Physician perception and recommendation of insulin pens for patients with type 2 diabetes mellitus. Curr Med Res Opin 2008;24:2413-22
14. Goldstein HH. Pen devices to improve patient adherence with insulin therapy in type 2 diabetes. Postgrad Med 2008;120:172-9
15. Wintergerst KA, Hinkle KM, Barnes CN, et al. The impact of health insurance coverage on pediatric diabetes management. Diabetes Res Clin Pract 2010;90:40-4
16. Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care 2008;31:430-2
17. Rhee MK, Slocum W, Ziemer DC, et al. Patient adherence improves glycemic control. Diabetes Educ 2005;31:240-50 (Pubitemid 40529013)
18. Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 2004;10:144-51 (Pubitemid 38332389)
19. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30 (Pubitemid 40847288)
20. Kuo Y-F, Raji MA, Markides KS, et al. Inconsistent use of diabetes medications, diabetes complications, and mortality in older Mexican Americans over a 7-year period: data from the Hispanic established population for the epidemiologic study of the elderly. Diabetes Care 2003;26:3054-60 (Pubitemid 37339498)
21. Gibson TB, Song X, Alemayehu B, et al. Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care 2010;16:589-600
22. Hunt J, Rozenfeld Y, Shenolikar R. Effect of patient medication cost share on adherence and glycemic control. Manag Care 2009;18:47-53
23. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011;33:74-109